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Abstract.  The tumor-promoting phorbol ester PMA 
induces changes in the histiocytic human lymphoma 
cell line U-937  akin to cellular differentiation (Ralph, 
P., N.  Williams, M.  A.  S.  Moore, and P.  B.  Litcofsky, 
1982,  Cell. Immunol.,  71:215-223)  and concomitantly 
stimulates the biosynthesis of plasminogen activator in- 
hibitor 2  (PAl 2) and of urokinase-type plasminogen 
activator (u-PA).  PAI 2  is found in a  nonglycosylated 
intracellular and a glycosylated secreted form. The 
former appears to be identical to PAI 2 previously 
purified from placental extracts and large-scale U-937 
cell cultures. The sixfold increase of PAl 2  antigen 
measured 24 h after PMA treatment in cell extracts 
and conditioned media is accompanied by an equal 
increase of active PAI 2  mRNA, whereas the 6  to 
13-fold  increase of u-PA antigen in the same samples 
is associated with only a  1.5-fold mRNA increase.  The 
increase of PAI 2,  but not of u-PA, biosynthesis re- 
quires transcription.  A  50-fold molar excess of PAI 2 
over u-PA is found in both extracts and conditioned 
media of PMA-treated cells. PAI 2  represents at least 
0.3%  of total de novo synthesized protein 24 h after 
induction with PMA. Thus, PAI 2,  but not u-PA, is an 
abundant product of this precursor analogue of the 
mononuclear phagocyte lineage, and might represent a 
new marker for monocyte/macrophage differentiation. 
p 
LASMINOGEN activators (PAs) are enzymes that con- 
vert the inactive zymogen plasminogen into the tryp- 
sin-like protease plasmin, which degrades fibrin as 
well as fibronectin and other extracellular matrix proteins 
(Dane et al.,  1985; Saksela, 1985; Collen, 1980). Two im- 
munologically and genetically distinct PAs are known: uro- 
kinase-type PA  (u-PA)  and tissue-type PA.  A  substantial 
body of evidence suggests that PAs play an important role in 
fibrinolysis (Collen,  1980),  inflammation (Vassalli  et al., 
1976), invasive and metastatic growth (Dane et al.,  1985; 
Markus, 1984; Ossowski and Reich, 1983), and other forms 
of cell migration (Valinsky  et al.,  1981). Therefore, much 
effort has been devoted to the study of the hormonal regula- 
tion of PA biosynthesis, using as an assayable endpoint PA 
activity in conditioned media and/or cell extracts (Dane et 
al.,  1985; Saksela,  1985). Recent results,  however,  have 
shown that u-PA is synthesized and secreted as a single chain 
proenzyme (Wun et al., 1982; Husain et al., 1983) and that 
many cells synthesize, often under hormonal control, spe- 
cific  PA  inhibitors  (PAIs)  (Seifert  and  Gelehrter,  1978; 
Crutchley et al.,  1981; Van Mourik et al.,  1984; Chapman 
and Stone, 1985). Hence, the information obtained by PA ac- 
tivity measurement alone is of limited value.  Cells of the 
histiocytic lymphoma cell line U-937 (Sundstr6m and Nils- 
i. Abbreviations  used in this paper: PA(s), plasminogen  activalor(s); PAI(s), 
PA inhibitor(s); u-PA, urokinase-type PA. 
son, 1976) differentiate in the presence of PMA and acquire 
characteristics  of monocytes/macrophages  (Ralph  et  al., 
1982). Previous work suggested that this differentiation was 
accompanied by an increase in PAl  activity in the condi- 
tioned medium (Vassalli et al., 1984; Kruithof et al., 1986). 
This activity was found to be immunologically related to a 
PAl  found  in  placental  extracts  (Vassalli  et  al.,  1984); 
Kruithof et al.,  1986; Kopitar et al.,  1985; /~stedt et al., 
1985) but different from protease nexin (Vassalli et al., 1984; 
Kruithof et al.,  1986; Scott and Baker,  1983) and a  PAl 
purified from endothelial cells (van Mourik, et al.,  1984; 
Vassalli et al.,  1984; Kruithof et al.,  1986). Following the 
nomenclature  recommendations  of the  subcommittee  on 
fibrinolysis of the International Society of Thrombosis and 
Hemostasis, we refer to the PAl purified first from endo- 
thelial cells (Van Mourik et al.,  1984) as PAl  1 and to the 
PAl purified first from placental extracts (/~stedt et al., 1985) 
as  PAl  2.  Using  the  plasminogen-dependent  fibrin  agar 
zymography technique (Granelli-Piperno and Reich,  1978) 
u-PA (but not tissue-type PA) was also found to be produced 
by U-937 cells (Vassalli et al., 1984). Taking into considera- 
tion the recent advances in the biochemistry of the fibrino- 
lytic system, we have studied the coordinate modulation of 
u-PA and PAl 2 biosynthesis by new, specific, and quantita- 
tive methods, determined the relative contribution of tran- 
scription, translation, and secretory processes on u-PA and 
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vestigated  the distribution of the different molecular forms 
of both u-PA and PAl 2. 
Materials and Methods 
Materials 
Imidazole, Tris, Tween 80, phenol, bovine serum albumin, sodium azide, 
Triton X-100, boric acid, sodium tetraborate, and lithum chloride were ob- 
tained from Fluka AG, Buchs, Switzerland. Bromopbenolblue, glycine, eth- 
anol, and trichioroacetic acid were obtained from E. Merck, Darmstadt, 
Federal  Republic  of Germany.  Pyroglu-gly-arg-p-nitroanilide was  from 
Bachem, Basel,  Switzerland.  All reagents for polyacrylamide gel elec- 
trophoresis in the presence of sodium dodecyl sulfate (SDS PAGE)  and 
nitrocellulose membranes were from Bio-Rad Laboratories,  Richmond, 
CA. Molecular mass standard proteins for SDS PAGE (phosphorylase b, 94 
kD; bovine serum albumin, 67 kD; ovalbumin, 43 kD; and carboanhydrase, 
30  kD),  and  Sephadex G-25  were obtained from Pharmacia,  Uppsala, 
Sweden. Sucrose, prestained protein standards employed in immunoblotting 
experiments (phosphorylase B, 97 kD; bovine serum albumin, 68 kD; oval- 
bumin, 43 kD;  and ¢t-ehymotrypsinogen, 26 kD) and low melting point 
agarose were from Bethesda Research Laboratories, Inc., Gaithersburg, 
MD. XAR-5 films for autoradiography and X-omatic intensifying screens 
were from Kodak, Lausanne, Switzerland. Proteinase K and lithium do- 
decyl sulfate were from Boehringer Mannheim GmbH, Mannheim, Federal 
Republic of Germany. Oligo dT cellulose type 2 was from Collaborative Re- 
search, Inc., Cambridge, MA. NP-40 was from Calbiochem, La Jolla, CA. 
RPMI 1640 was from Seromed, Bioehrom, Federal Republic of Germany. 
Glutamine was from BioMtrieux, Charbonni~res-les-Bains, France. FCS 
was from Gibco, Paisley, United Kingdom. High molecular mass u-PA was 
from the Green Cross, Osaka, Japan. Plasminogen-rich fibrinogen from bo- 
vine origin (containing 3 % plasminogen on a weight per weight basis), lot 
No.  151910, was obtained from Organon Teknika, Oss, The Netherlands. 
Merthiolate was from Lilly,  Indianapolis, IN. Affinity-purified ~25I-protein 
A and rabbit reticulocyte lysate were from Amersham International, Amer- 
sham,  United  Kingdom.  [35S]Methionine  and  EN3HANCE  were  from 
New England Nuclear, Dreieich, Federal Republic of Germany. Picofluor 
scintillation fluid was from Packard Instrument Company, Ztirich, Switzer- 
land. PMA was from P-L Biochemicals, Inc., Milwaukee, WI (a stock solu- 
tion of 100 Ixg/ml in ethanol was stored at -200C). Nonfat dry milk (Lorso) 
was from Stalden, Konolfingen, Switzerland. Donkey IgG anti-rabbit IgG 
bound to  cellulose (Sac-Cell) was from Wellcome, Beckenham,  United 
Kingdom. PBS had the following composition: 8 g/liter NaCI, 0.2 g/liter 
KCI,  1.44 g/liter NaH2PO4  • 2 H20 and 0.2 g/liter KH2PO4. 
Cell Culture 
U-937  cells, originally developed from the pleural exudate of a  diffuse 
histiocytic lymphoma (Sundstrom and Nilsson, 1976) were grown in suspen- 
sion culture in RPMI  1640 medium supplemented with 5 % FCS, 2 mM 
glutamate and incubated in a  5% CO2 and 95%  air atmosphere at 37°C. 
Cells were collected by centrifugation, washed three times with PBS, and 
resuspended at a concentration of 106 cells/ml in RPMI  1640 containing 
PMA at the concentrations indicated in the results section. After incubation, 
media were collected, centrifuged (10 rain, 4,000 g and 4°C) and stored at 
-70°C until further use. For experiments requiring higher protein concen- 
trations, media were boiled for 5 min in 1% SDS, dialyzed against 0.05% 
SDS in H2O, dried, and stored at 4°C until dissolved in H20 to a chosen 
concentration. 
PAl 2 Extraction of  Cells after Stimulation with PMA 
The adherent cells were washed three times with PBS, scraped off with a 
rubber policeman, sedimented by centrifugation, suspended in extraction 
buffer (0.1% NP-40 in PBS), homogenized in a Potter-Elvehejm homoge- 
nizer and centrifuged for 15 min at 10(300 g. The supernatants were stored 
at  -70°C until further use. 
Activity Assay  for u-PA and PAl 
u-PA activity was measured using the chromogenic substrate pyroglu-gly- 
arg-p-nitroanilide. Assays of PAI 2 activity were carried out in 96-well mi- 
crotiter plates as previously described (Kruithof et al.,  1986). 50-p.1 sam- 
pies, suitably diluted with 50 mM imidazole, pH 7.4,  140 mM NaCI,  1 
mg/ml albumin, and 0.01% Tween-80 were mixed with 50 gl of a 50 U/ml 
u-PA solution. After a 10-rain incubation at 370C, 100 I~1 of  0.6 mM pyroglu- 
gly-arg-p-nitroanilide in 0.1 M Tris-HC1,  pH 8.8, was added. The increase 
of absorbance at 405  nm was measured in a  micro-ELISA-reader. The 
results were compared with those of a standard curve of u-PA. The inhibitor 
activity of  the sample was defined as the difference between original activity 
(50 U/ml) and remaining activity as extrapolated from the standard curve 
and multiplied by the dilution factor.  Activity measurements by the fibrin 
plate technique were performed as described by Astrup and Miillertz (1952). 
Radioimmunoassay for u-PA and PAl 2 Antigen 
The samples to be tested (100 ~tl, suitably diluted in immunoassay buffer: 
50 mM Tris-HC1, pH 7.4, 0.2 M NaC1,  10 mM EDTA, 0.1% albumin) were 
incubated for 4  h  at room temperature in the presence of 100  gl rabbit 
anti-human u-PA IgG, diluted to a concentration that bound 50% of 1251- 
u-PA in the absence of sample. Then 50 I11 of ~25I-u-PA (40,000  cpm/ml) 
was added and the sample incubated overnight at 4°C. Antigen-antibody 
complexes were precipitated by 30 rain incubation at room temperature with 
100 gl Sac-Cell (immobilized donkey IgG anti-rabbit IgG). The cellulose 
was washed three times with 2 mi of 0.15 M NaC1 and bound radioactivity 
counted in a  "/-counter.  Results were evaluated using the empirical logit 
transformation of Rodbard et al. (1974). The radioimmunoassay for PAI 2 
was performed essentially like that of u-PA, using rabbit anti-PAl IgG. 
Electrophoretic Procedures 
SDS PAGE was performed as described by Laemmli (1970) employing 10% 
separating gels. Reverse fibrin autography was performed as described by 
Erickson et al.  (1984),  using the following modifications. The gel was 
shaken for 75 min in 1% Triton X-100 and quickly rinsed in H20 before be- 
ing placed on a u-PA containing fibrin-agarose underlay,  which was pre- 
pared as follows. 15 ml of plasminogen-rich fibrinogen (10 mg/ml in 50 mM 
imidazole, 140 mM NaC1, pH 7.4),  10 ml of 2.5% agarose in H20 kept at 
54°C, 2 ml of thrombin (1 U/ml in imidazole-NaCl), and 0.54 ml of u-PA 
(2 U/ml in Imidazole-NaCl, 1% albumin) were mixed and injected immedi- 
ately between two glass plates separated by 0.75-mm spacers. Proteins were 
stained by Coomassie Brilliant Blue as described (Laemmli,  1970). Gels 
were prepared for fluorography using EN3HANCE,  according to the in- 
structions of the manufacturer. 
Concanavalin A (Con A )-Sepharose Chromatography 
Conditioned medium of a  3-d culture of phorbol ester-stimulated U-937 
cells was concentrated by ultrafiltration through a  Pellikon membrane as 
previously described (Kruithof et al., 1986). The concentrate containing 50 
mg of total protein was dialyzed against 0.02 M Tris-HCl, 0.5 M NaCI, pH 
7.4, and passed over a 5-ml column of  Con A-Sepharose. After washing with 
the Tris-NaCl buffer, the column was eluted with 0.5 M methyl-ct-o-manno- 
pyrannoside. 
lmmunoblotting 
Immunoblot analysis was performed according to Towbin et al. (1979) in- 
cluding the modifications of  Johnson et at. (1984). After SDS PAGE the pro- 
teins were electrophoretically transferred to a nitrocellulose sheet using a 
Transblot cell (Bio-Rad Laboratories) containing 17 mM Tris, 67 mM gly- 
cine, pH 8.3, 0.07%  SDS, and 17%  methanol. Experiments using ~251-1a- 
beled antigen established that transfer was more than 95% under these con- 
ditions. The nitrocellulose sheet was shaken successively in the following 
solutions: 1 ×  10 min in 50 mM Imidazole, 140 mM NaCI, pH 7.4;  2  × 
15 min in BLOVI~ (0.02 M Tris, 0.5 M NaCI, and 50 g/liter nonfat dry 
milk, adjusted to pH 7.5;  Johnson et al.,  1984); then incubated overnight 
at 4°C in 50 ml BLOTTO containing 1.2 ~g/ml of immunoaffinity-purified 
anti-PAI IgG (Kruithof et al.,  1986) or 0.4 p.g/ml of anti-u-PA IgG (Wan 
et al., 1982) followed by 2  x  15 min in BLOTTO; 4 h at room temperature 
with ~25I-protein  A (10 p.Ci of a 30-mCi/mg preparation) in BLOTTO;  and 
2 h with BLOTTO.  The nitrocellulose sheet was rinsed with water, dried, 
and exposed to Kodak XAR film. Thereafter the radioactive bands were cut 
out of the nitrocellulose and counted in a ~¢-counter (Howe and Hershey, 
1981; Vaessen et al., 1981). Alternatively, after incubation with the anti-PAl 
IgG, the nitrocellulose was washed twice with BLOTTO and incubated for 
3 h with goat anti-rabbit IgG conjugated with horseradish peroxidase (Bio- 
Rad Laboratories) used at a dilution of 1:200, washed twice with BLOVIO, 
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FJS]Methionine Biosynthetic Labeling 
and lmmunoprecipitation 
Cells were collected by centrifugation (10 min, 400 g), washed three times 
with PBS,  resuspended  in methionine-free RPMI  1640, and starved for 
methionine for  2  h.  Cells  were  then  incubated for  4  h  at  37°C  with 
[35S]methionine (50  IxCi/ml) and  PMA  (10 ng/ml).  Subsequently,  10% 
vol/vol of regular RPMI 1640 was added.  After 24 h more of incubation, 
the media were harvested and the cells extracted as described above. Total 
protein in cellular extracts  and conditioned media was precipitated  by ad- 
justment to 10% trichloroacetic acid and incubated on ice overnight.  The 
precipitates  were recovered by centrifugation, washed three times with 10% 
trichloroacetic acid, and counted for total incorporation of radioactivity. 
Immunoprecipitation was performed essentially as described (Mihara and 
Blobel, 1980) except that Sac-Cell was used instead of protein A-Sepharose 
for the recovery  of antigen-antibody complexes. 
RNA Extraction 
RNA was prepared by a combination of SDS/proteinase  K digestion  and 
phenol/chloroform extraction.  Cells were incubated for 15 rain at 37°C in 
extraction buffer (25 mM Tris-HCl, pH 7.35, 0.1 M NaCl, 7.5 mM EDTA, 
20 txg/ml polyvinylsulfate,  2.4% SDS, and 250 ltg/ml proteinase K; Lizardi 
and Engelberg,  1979). 1 vol of cell lysate, collected in a 50-ml tube (Falcon 
Labware,  Oxnard, CA),  was mixed with l vol of phenol/chlorofoma/ether 
(50:50:1), homogenized using a polytron homogenizer for 15 s at the highest 
speed setting, vigorously shaken for 30 rain, and centrifuged at 4,000 g for 
10 min. The aqueous phase was collected,  adjusted to 0.2 M NaC1, mixed 
with an equal volume of isopropanol  cooled to  -70"C, and centrifuged at 
10,000 g for 10 rain. The pellet was then dissolved  in H20,  reprecipitated 
with ethanol, and redissolved in 0.07% lithium dodecyl sulfate in water. The 
mixture was adjusted to 2.8 M lithium chloride, incubated at 4°C for 4 h, 
and centrifuged at ll,000 rpm for 10 rain. After dissolving of the pellet in 
H20, the solution was ethanol precipitated  and stored at -70°C. Poly(A) + 
RNA was selected by hybridization to oligo dT cellulose essentially as de- 
scribed by Aviv and Leder (1972), and following  the instructions of the 
manufacturer (Collaborative  Research, Inc.). 
In Vitro Translation 
In vitro biosynthesis of protein was performed in a rabbit reticuloeyte cell- 
free system, as described by Pelham and Jackson (19"/6), using a reagent kit 
from New England Nuclear.  1 p.g of poly(A)  + RNA in 25 ~tl total reaction 
volume was translated for 90 min. Total radioactivity  incorporated into pro- 
tein was subsequently determined by precipitation in 10% trichloroacetic 
acid. The proportion of specific  PAI 2 translated was determined by im- 
munoprecipitation as described above and by Maniatis et al. (1975). 
Northern Blot Hybridization 
pUK 0321, a recombinant  pUC 9 derivative (Vieira and Messing, 1982) con- 
taining u-PA cDNA, was isolated  from a cDNA library constructed from 
mRNA from HT 1080 fibrosarcoma cells (Hession, K., H. Meade, W.-D. 
Schleuning,  unpublished results) by screening with a mixed oligonucleotide 
probe,  synthesized  according to the published protein sequence of u-PA 
(Giinzler et al.,  1982).  Electrophoresis was performed using 1% agarose 
gels containing 20% formaldehyde  and RNA transferred to nitrocellulose 
filter  paper.  Hybridization with radioactive  pUK 0321 (labeled by nick 
translation; Maniatis et al.,  1975) and washing of the filters was performed 
as described (Thomas,  1980). 
Results 
PMA-induced Biosynthesis of  PAI 2 and u-PA in U-937 
Cells Is lime-and Dose-Dependent 
The treatment of U-937 cells with increasing concentrations 
of PMA resulted in a concentration-dependent accumulation 
of PAI 2  in the culture medium. If PAI 2  activity was mea- 
sured  24  h  after  stimulation,  maximal  induction  was  ob- 
Figure 1.  Biosynthesis of PAl 2  and u-PA activity by U-937 cells; 
response to increasing doses of PMA. (Top) Demonstration of u-PA 
and PAl 2 activity in conditioned media by reverse fibrin autography 
(Erickson et al.,  1984).  100 ~tl conditioned media, mixed with 20 
ltl 6x  sample buffer were charged per track;  underlays were in- 
cubated for U h at T/°C. u-PA activity is visualized as a clear band 
at Mr 54,000, PAl 2 activity as two opaque zones at Mr 47,000 and 
60,000.  (Middle)  17-h incubation at 37°C.  (Bottom)  PAl 2  activity 
measured in the conditioned media 24 (solid circle) and 48 h (solid 
square)  after PMA treatment. 
served at a concentration of 4 ng/ml (Fig. 1, bottom). If PAI 
2 activity was measured after 48 h, the dose-response curve 
did not reach a  plateau.  Separate  experiments employing 
trypan blue exclusion as a criteria for cell viability, however, 
suggested that this was due to a release of intracellular PAl 
2 from a proportionately increasing number of dead cells. 
The effect of PMA was also visualized by reverse fibrin au- 
tography (Fig. 1, top). Under the chosen conditions, which 
are described in detail in Materials and Methods, both u-PA 
and PAI could be visualized by this technique. After 11 h of 
incubation,  activation of plasminogen by exogenous u-PA 
added to the indicator gel was not sufficient to produce lysis. 
Where u-PA was present in the separation gel, however, a ly- 
sis zone was generated at a position corresponding to 54 kD 
(Fig. 1, top). After 17 h of incubation, fibrin in the indicator 
gel was completely lysed, except in positions where PAI ac- 
tivity had been present. The position of  the two opaque bands 
that increased after phorbol ester treatment corresponded to 
50 and 60 kD (Fig. 1, middle). In separate experiments with 
purified PAI 2, we established that PAI 2 can be visualized 
by this technique, although its activity is partially destroyed 
by SDS. The increase of PAI 2 activity was found to be time- 
dependent both in cellular extracts and conditioned media 
(Fig. 2). Conspicuously, the large majority of activity (85 %) 
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Figure 2. Accumulation of PAl 2 activity in extracts (solid triangle) 
and conditioned media (open triangle) of U-937 cells after treat- 
ment with PMA (10 ng/ml) and in extracts (solid circle) and condi- 
tioned media (open circle) of untreated controls. 
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Figure 4. Time-dependent accumulation of u-PA antigen (as deter- 
mined by radioimmunoassay) in media conditioned by U-937 cells 
treatexl with 10 ng/ml of PMA (open triangle). Media of untreated 
control cells (open circle). 
was present in cellular extracts. U-PA activity, present in the 
conditioned media, was evidenced by the  sharp lysis zone 
corresponding to 54 kD (Fig. 1). By comparing the width of 
the lysis zone with lysis zones generated by standard amounts 
of u-PA, this activity could be estimated to represent ~1 ng 
u-PA/ml. It could therefore not be determined by the colori- 
metric assay, which reaches its sensitivity limit at ~10  Ixg 
u-PA/ml  (our unpublished  results).  Using the more sensi- 
tive fibrin plate technique (Astrup and Miillertz,  1952) with 
which concentrations as low as 0.2 ng/ml can be determined, 
there  was,  nevertheless,  no u-PA  activity detectable.  This 
was most probably due to the presence of high excess of PAl 
2  and not to the fact that u-PA was present in its pro-form, 
since pro-u-PA is also detectable in this assay system (our 
unpublished results), apparently because it is converted into 
u-PA by the presence of trace amounts of plasmin. We there- 
fore quantified u-PA antigen by a radioimmunoassay. Maxi- 
mal release of u-PA into the medium occurred at the same 
PMA concentration as that of PAl 2  (Fig.  3).  U-PA levels 
only started to rise 12 h after stimulation by PMA (Fig. 4). 
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Figure 3. u-PA antigen in media conditioned by U-937 cells in re- 
sponse to increasing doses of PMA as determined by a radioimmu- 
noassay; 24 (solid circle)  and 48 h  (solid square)  after treatment. 
Molecular Heterogeneity of  ExtraceUular and 
Intracellular PAl 2 and u-PA Antigen: an Assessment 
by Quantitative lmmunoblot Analysis and 
Biosynthetic Labeling 
Reverse fibrin autography (Fig.  1) revealed a molecular bet- 
erogeneity of PAl 2.  To study the different forms of PAI 2 
in more detail and to quantify each form separately, we es- 
tablished a quantitative immunoblot assay, using ~25I-labeled 
protein  A  as  indicator  protein,  as  previously  described 
(Vaessen et al.,  1981; ~mmle  et al.,  1986).  Extracellular 
PAl 2  was almost exclusively (but not entirely) found as a 
60-kD species and was increased approximately sixfold after 
24 h of PMA stimulation (Fig. 5, lanes b and c). Intracellular 
PAI 2 consisted of a closely spaced doublet of 47 kD and in- 
creased approximately sevenfold under the same conditions 
(Fig. 5, lanes d and e), The intracellular form was predomi- 
nant (85 % of the total antigen) both before and after PMA 
stimulation. The increase in PAl 2 activity and antigen was 
matched by a  proportional increase in biosynthetically la- 
beled PAl 2 in the conditioned medium 24 h after PMA treat- 
ment (Fig. 6). Thus, PMA did not stimulate the processing 
and subsequent secretion of the 60-kD form of PAl 2  from 
an existing storage pool, but stimulated its de novo synthesis. 
The proportion of PAl 2  antigen in relation to total newly 
Figure 5.  Quantitative immu- 
noblotting assay of PAl 2 an- 
tigen  in  conditioned  media 
(lanes b and c) or cell extracts 
(lanes d and e) of U-937 cells 
24 h after treatment with 10 ng/ 
ml of PMA (lanes c and e) or 
of untreated controls  (lanes b 
and d).  Purified  PAl 2  (lane 
a). By comparison with a stan- 
dard  curve  constructed  in  a 
parallel experiment the following amounts (b-d expressed per 106 
cells) were obtained: lane a, 150 ng; lane b, 46 ng; lane c, 275 ng; 
lane d, 295 ng; lane e,  1960 ng. 
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labeled PAl 2 from conditioned 
media of U-937 cells 24 h af- 
ter  PMA  treatment  (lanes  c 
and  d)  or  from  nontreated 
controls (lanes  a  and b).  100 
gl  of  conditioned  medium 
were subjected to immune pre- 
cipitation  using  affinity-pu- 
rified anti PAl 2 IgG (lanes a 
and  c)  or  nonimmune  IgG 
(lanes b and d). Immune pre- 
cipitates  were  analyzed  by 
SDS PAGE, followed by treat- 
ment with EN3HANCE, dry- 
ing, and exposure for 3 wk to 
Kodak XAR film at  -70°C. 
Figure 8.  Separation  of the 
60- and 47-kD forms of PAl 2 
by affinity chromatography on 
Con A-Sepharose. Crude, con- 
centrated  U-937-conditioned 
medium  was  passed  over  a 
column of Con  A-Sepharose 
as described in Materials  and 
Methods.  After washing,  the 
column was eluted with 0.5 M 
methyl-tt-D-mannopyranoside.  The  fraction  not  retarded  by the 
column (left) and the eluted fraction (right) were subjected to SDS 
PAGE in a 10% gel, either before or after a 15-min incubation  with 
a  five-fold excess  of low  relative  molecular mass u-PA,  electro- 
transferred  to nitrocellulose  and  revealed  by immunoperoxidase 
staining using immunopurified  rabbit anti-PAl antibodies  and goat 
anti-rabbit IgG antibodies  conjugated  to horseradish peroxidase. 
synthesized  protein  as  measured  by  trichloroacetic  acid- 
precipitable,  versus  -immunoprecipitable  radioactivity  in- 
creased  10-fold from 0.03  to 0.3%  in cellular  extracts  and 
about sevenfold from 3 to 20%  in conditioned media (data 
not  shown).  SDS  PAGE  of  immunoprecipitates  obtained 
from cellular extracts revealed, besides bands migrating like 
PAI 2, considerable amounts of contaminating protein even 
after extensive washing of the immunoprecipitates.  This in- 
dicates that U-937 cells contain protein(s)  that bind to IgG 
(probably the Fc receptor and/or other unknown proteins). 
This is also the most likely reason for our failure to establish 
a radioimmunoassay for intracellular PAl 2 antigen. In con- 
trast to the band migrating like PAl 2,  however,  the bands 
representing  contaminating  proteins  did  not appear  to  in- 
crease after PMA treatment (data not shown).  Intracellular 
u-PA antigen displayed a  molecular mass indistinguishable 
from that of commercial urokinase (Fig.  7,  lanes a, d,  and 
e),  and increased approximately  10-fold after 24 h of PMA 
treatment.  Extracellular  u-PA antigen  was found predomi- 
nantly as a heterogeneous form with molecular masses rang- 
ing from 60 to 70 kD (Fig.  7,  lanes b  and c) and increased 
approximately sixfold. Zymography indicated that this form 
was inactive (Fig.  1).  In contrast,  the active u-PA revealed 
in Fig. 1 was hardly visible after immunoblotting, apparently 
because its concentration was close to the lower limit of de- 
tection of this test  (below  1 ng/ml). 
The 60-kD Form of  PAI Is Glycosylated 
To investigate the possibility that the molecular heterogene- 
ity of PAl 2 was caused by differential glycosylation, a mix- 
Figure  7.  Quantitative  immu- 
noblot assay  of u-PA antigen 
in conditioned media (lanes b 
and c) or cell extracts (lanes d 
and e) of U-937 cells 24 h after 
treatment  with  10 ng/ml PMA 
(lanes c and e) or of untreated 
controls (lanes b and d). Puri- 
fied high molecular mass u-PA 
(lane a). By comparison with 
a standard curve constructed in a parallel  experiment,  the following 
amounts (lanes b-d expressed  per  106 cells)  were obtained:  (lane 
a), 40 ng; lane b, 1 ng; lane c, 2.8 ng; lane d, 6 ng; lane e, 39 ng. 
ture  of the  two  forms  was  passed  over  a  column  of Con 
A-Sepharose. Only the 60-kD form was retained by the col- 
umn, whereas the 47-kD doublet passed unretarded (Fig. 8). 
Thus,  the 60-kD  form contains  carbohydrates  that bind  to 
Con A-Sepharose, whereas the 47-kD form does not (Fig. 8). 
The functional activity of the two forms ofPAI 2 was similar, 
since both  were able to form complexes  with  low  relative 
molecular mass u-PA (Fig.  8).  Furthermore,  the kinetics of 
inhibition of u-PA by the two forms of PAI 2  was identical 
(unpublished  observations).  The relative molecular masses 
of the complexes of both glycosylated and nonglycosylated 
PAI 2  with low molecular mass u-PA are less than the sum 
of their relative molecular masses.  This implies cleavage of 
the  inhibitor  during  complex  formation  as  discussed  by 
Kruithof et al.  (1986). 
The Increase of  PAI 2 Requires Gene Transcription 
and Is Accompanied by an Equal Increase of mRNA 
When cells were cultured for 24 h  in the presence of PMA 
and  either  ct-amanitine  (10  Ixg/ml)  or  cycloheximide  (1 
pg/ml),  PAI 2  activity in both cellular extracts  and condi- 
tioned media was decreased 80 and 85 %, respectively, with 
respect to controls that had been treated with PMA alone. 
Figure 9. Protein biosynthesis 
in a rabbit reticulocyte-derived 
cell-free  system  directed  by 
mRNA from U-937 cells that 
were  maintained  for 24 h  in 
serum-free  RPMI (lanes a, c, 
and  e)  or  serum-free  RPMI 
supplemented  with  10  ng/ml 
PMA (lanes b, d, and f). Af- 
ter 90-min reaction time, total 
protein  of 1 p] of the sample was precipitated  with trichloroacetic 
acid (lanes  a  and b) and 24 gl of the sample  were subjected  to 
immunoprecipitation,  using  anti-PAl  2  IgG (lanes  c  and  d)  or 
nonimmune IgG (lanes e and f).  Precipitates  were solubilized  by 
boiling in lx sample buffer, containing  10 mM dithiothreitol,  elec- 
trophoresed  through  SDS  polyacrylamide gels  (L/immli,  1970), 
treated  with  EN3HANCE, dried,  and exposed  for 5 d to Kodak 
XAR-film.  The PAl 2  band is  marked with  an arrow.  The band 
above represents  an artifact,  which frequently contaminates  [35S]- 
methionine. 
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ysis  of mRNA  from  U-937 
cells maintained for 24 h  in 
serum-free  RPMI  (lane  a) 
or serum-free RPMI  supple- 
mented with  10 ng/ml PMA 
(lane b). 10 ng poly(A)  ÷ RNA 
were loaded per slot, electro- 
phoresed through a 1% agarose 
gel containing 20% formalde- 
hyde, transferred to nitrocellu- 
lose (Thomas, 1980), and hy- 
bridized  to a u-PA  cDNA probe 
that had been 32p-labeled by nick translation to a specific activity 
of 0.5 x  l0  s cpm/Ixg. Filters were washed (Thomas, 1980) and ex- 
posed to Kodak XAR film at  -70°C. 
The increase of u-PA antigen was unaffected by a-amanitine 
but reduced 60 % by cycloheximide. The relative amount of 
PAl 2 mRNA in induced and noninduced cells was compared 
by in vitro translation experiments, mRNA from both cell 
types  was  used  to  direct protein biosynthesis  in  a  rabbit 
reticulocyte-derived  cell-free system. PAl 2 antigen was im- 
munoprecipitated from the mixtures and analyzed by SDS 
PAGE. The relevant bands were cut out, counted, and com- 
pared with total incorporated counts (measured by trichloro- 
acetic acid precipitation). Upon PMA stimulation, the quan- 
tity of PAl 2 antigen synthesized in the in vitro translation 
system increased sixfold. The proportion of PAI 2-specific 
mRNA increased from 0.04 to 0.25 % (Fig. 9). The levels of 
u-PA mRNA were too low for characterization by in vitro 
translation and immunoprecipitation. We therefore resorted 
to Northern blot analysis. The specificity of this assay was 
previously established using mRNA from HT 1080 fibrosar- 
coma cells  and  Bowes  melanoma  cells.  Whereas  mRNA 
from the former line,  a  known producer of u-PA,  gave a 
strong band at about 22 S, the mRNA of  the latter line, which 
does  not  produce  u-PA  antigen,  gave  a  negative  result 
(Schleuning, W. D., and R. Medcalf, unpublished observa- 
tions).  The  increase  of u-PA-specific mRNA  in  induced 
versus noninduced U 937 cells was only 1.5 times, as com- 
pared with a 6- to 13-old increase in intra- and extracellular 
u-PA antigen (Fig.  10). 
Discussion 
The association of PA biosynthesis with a variety of biologi- 
cal processes that involve cell migration and tissue remodel- 
ing has been extensively documented (Dane et al.,  1985; 
Saksela, 1985; Vassalli et al., 1976; Markus, 1984; Ossowski 
and Reich, 1983). The classical example of a migratory cell 
is the macrophage. Its PA was first described by Unkeless et 
al. (1974) and subsequently studied by Hamilton et al. (1976), 
Vassalli et al. (1976), and VassaUi and Reich (1977). In these 
early reports, however, the molecular species of PA were not 
identified, and proenzyme activation and specific inhibition 
not investigated. U-937 cells were chosen to reexamine this 
work, because they are akin to precursors of the mononucle- 
ar  phagocyte lineage  and  differentiate in  the  presence of 
PMA, acquiring monocyte/macrophage enzymatic and sero- 
logical  markers  (Ralph  et  al.,  1982).  Macrophages  and 
U-937 cells synthesize pro-u-PA and a PAI 2 immunologi- 
caUy  related to a  PAl in placental extracts (/~stedt et al., 
1984; Kopitar et al.,  1985; Vassalli et al.,  1984; Kruithof et 
al.,  1986). Our results provide a quantitative assessment of 
the modulation of this synthesis during differentiation and 
demonstrate the need of immunological assays,  since u-PA 
activity was undetectable in unfractionated conditioned me- 
dia or cellular extracts. 
PAl 2 activity and PAl 2 antigen measurements correlated 
reasonably well. Assuming a specific activity of 1 x  105 in- 
hibitory units (IU)/mg (based on a specific activity of u-PA 
of 1 x  105 U/mg, equimolar complex formation, and a rela- 
tive molecular mass of PAl 2 close to u-PA) the measured ac- 
tivities corresponded approximately to the quantity of anti- 
gen present (Figs. 1 and 5). Hence, most PAl 2 is fully active 
in both cellular extracts and conditioned media and is not 
present in  a  latent form or complexed to  PA,  like  PAl  1 
purified  from  endothelial  cells  (Hekman  and  Loskutoff, 
1985;  Sprengers et al.,  1984). 
IntraceUular  and  extraceUular  PAI  2  exhibit  the  same 
specific activity (Kruithof, E. K. O., unpublished data) but 
differ in their molecular masses. Experiments involving fixa- 
tion of the protein to Con A-Sepharose demonstrated that 
secreted 60-kD PAl 2 is a glycoprotein, whereas the two in- 
tracellular forms (which do not bind to Con A-Sepharose) 
are either glycosylated differently, or not at all. Current con- 
cepts of protein compartmentalization imply that secretory 
proteins are synthesized on bound ribosomes and core-gly- 
cosylated co-translationally during insertion into the rough 
endoplasmatic  reticulum (reviewed by Dunphy and  Roth- 
man,  1985).  The N-linked precursor oligosaccharide chain 
contains glucose,  mannose,  and N-acetyl glucosamine.  In 
the Golgi stack the high mannose precursor chains are par- 
tially degraded and remodeled by several glycosyltransfer- 
ases. All forms along this pathway bind Con A. Should this 
scheme be verified for all secretory proteins, it would appear 
as if the intracellular PAI 2 is not targeted to the secretory 
pathway.  Then the high intracellular concentration of PAI 2 
suggests an intracellular function, which is at present un- 
known. It was shown in two important recent contributions 
that translocation and modification of a yeast secretory pro- 
tein may happen posttranslationally in  an ATP-dependent 
process  (Waters  and  Blobel,  1986;  Hansen et al.,  1986). 
Such a mechanism has so far not been found in animal cells 
but likewise has not been rigorously excluded. It can there- 
fore not be ruled out that PAl 2 is translated, stored in an un- 
modified form, and channeled into the secretory pathway in 
response to still undefined signals. 
Intracellular u-PA antigen migrated on SDS PAGE similar 
to urinary high molecular mass u-PA. Surprisingly, extracel- 
lular u-PA antigen was found predominantly in an enzymati- 
cally inactive form of three closely spaced bands of 67-70 
kD. We considered the possibility that these bands presented 
an artifact due to unspecific binding of the antibody em- 
ployed.  This,  however, appears unlikely for the following 
reasons:  (a)  immunoaflinity-purified antibodies were used 
throughout the experiment; (b) the bands were absent in con- 
trois where nonimmune IgG was employed; and (c) a surplus 
of urokinase antigen competed for binding (data not shown). 
There is so far no clue to the origin, the function, or the bio- 
logical significance of these forms. Judging from the molecu- 
lar mass, it might represent a complex of low molecular mass 
u-PA with an inhibitor, which, however, does not react with 
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tially degraded form of a complex of u-PA with its cellular 
binding site  (Vassalli  et al.,  1985;  Stoppelli  et al.,  1985; 
Stoppelli et al., 1986). This cellular binding site (also called 
the u-PA receptor) constitutes an important new element of 
the plasminogen-activating enzymatic system and an attrac- 
tive subject for future work.  We note that Stoppelli et al. 
(1986), in their study on the u-PA receptor, have observed 
u-PA antigen of similar relative molecular mass as that de- 
scribed here in conditioned media of A-431 cells,  and have 
likewise failed to present a fully satisfactory interpretation. 
We are presently  making  efforts  to determine  the definite 
identity of this abnormally migrating u-PA antigen. 
Calculations of the second order rate constant of complex 
formation (Kruithof et al.,  1986) and the concentrations of 
enzyme and inhibitor in cellular extracts (Figs. 2, 6, and 8) 
indicate that almost all u-PA should form complexes  with 
PAl 2 within minutes if in an active form. As this is not the 
case,  pro-u-PA appears to be unable to react with PAl 2. 
Stimulation of u-PA and PAl 2 biosynthesis after PMA treat- 
ment was time- and dose-dependent, u-PA antigen increased 
to the same extent in the presence and absence of ¢t-amani- 
tine.  A  1.5-fold increase of u-PA-specific  mRNA  was  ob- 
served by Northern blot analysis. To account for the total in- 
crease of antigen, however, one would have to also assume 
an increased translation rate, or perhaps a decreased degra- 
dation of u-PA antigen in untreated cells.  Alternatively,  a 
higher increase of mRNA  could have occurred transiently 
and thus would not have been observed after 24 h. This is 
unlikely, however, because Qt-amanitine did not block the in- 
crease in u-PA antigen. No experiments were performed to 
discriminate  between  these possibilities.  24  h  after  PMA 
treatment,  PAI 2  antigen and activity increased  sixfold  in 
conditioned media and about sevenfold in cellular extracts. 
About 85 % of PAI 2 was found in cellular extracts. The 80% 
inhibition of this increase by ¢t-amanitine  indicates a contri- 
bution of de novo transcription. Representing at least 0.3 % 
of total protein synthesized 24 h after PMA induction, PAl 
2 has to be considered a major product of this monocytic cell. 
PAl 2 is present in a 50-fold molar excess over u-PA. It will 
be interesting to see whether authentic macrophages or other 
PA-producing cells also produce such large surplus of inhibi- 
tor, and how modulation of PAI 2 biosynthesis contributes to 
the extent of pericellular proteolysis in cell migration and tis- 
sue remodeling. 
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